<p>对于 <strong>Chemours 公司</strong>（纽约证券交易所代码：CC）股东来说，这一周表现平平，自最新季度财报发布以来，股价下跌了 17%，至 22.41 美元。整体情况并不理想，尽管分析师原本预期会有盈利，但公司却意外出现了每股 0.19 美元的法定亏损，营收为 14 亿美元。财报发布后，分析师们更新了他们的盈利模型，了解他们是否认为公司的前景发生了重大变化，或者一切如常，将会很有趣。我们认为读者会对分析师最新的（法定）盈利预测感兴趣，尤其是针对明年的预测。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行探索。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249061912-earnings-and-revenue-growth-1-dark-2/1778247092634?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249061912-earnings-and-revenue-growth-1-dark-2/1778247092634"/></p>
<p>纽约证券交易所：CC 盈利和收入增长 2026 年 5 月 8 日</p>
<p>考虑到最新的财报，Chemours 九位分析师的共识预测是 2026 年营收为 60.2 亿美元。这反映出与过去 12 个月相比，营收有 3.5% 的适度改善。预计盈利将有所改善，Chemours 预计每股报告法定盈利 1.21 美元。在这份财报发布之前，分析师们曾预测 2026 年营收为 60.4 亿美元，每股盈利（EPS）为 1.58 美元。分析师们似乎在最新财报发布后变得更加悲观。虽然营收预测没有变化，但每股盈利的预期却大幅下调。</p>
<p>查看我们对 Chemours 的最新分析</p>
<p>尽管下调了盈利预测，分析师们仍将目标股价上调了 9.8%，至 24.89 美元，这表明这些影响预计不会在长期内对股价造成压力。然而，从这些数据中我们可以得出其他结论，因为一些投资者在评估分析师的目标股价时也喜欢考虑预期的差异。最乐观的 Chemours 分析师将目标股价定为每股 30.00 美元，而最悲观的则为 17.00 美元。对于这只股票，确实存在不同的看法，但我们认为预期范围并不够宽泛，以至于暗示情况无法预测。</p>
<p>我们还可以从更大的背景来看待这些预期，例如这些预测与过去表现的对比，以及相对于行业内其他公司的预测是否更为乐观。例如，我们注意到 Chemours 的增长率预计将显著加快，预计到 2026 年营收将以年均 4.6% 的速度增长。这远高于过去五年每年 1.5% 的历史下降率。相比之下，我们的数据表明，行业内其他公司（有分析师覆盖）预计营收将以每年 5.2% 的速度增长。因此，尽管 Chemours 的营收预计将改善，但其增长速度似乎与整体行业大致相当。</p>
<h2>结论</h2>
<p>最重要的是，分析师下调了每股盈利的预期，显示出在这些结果发布后情绪明显下降。他们还重新确认了营收预期，预计公司将以与更广泛行业相似的速度增长。目标股价也有了不错的提升，分析师们显然认为公司的内在价值正在改善。</p>
<p>基于这一思路，我们认为公司的长期前景比明年的盈利更为重要。在 Simply Wall St，我们有 Chemours 到 2028 年的全系列分析师预估，您可以在我们的平台上免费查看。</p>
<p>话虽如此，仍然有必要考虑投资风险的潜在威胁。<strong>我们已识别出 Chemours 的 2 个警示信号</strong>（至少有 1 个让我们感到不安），理解这些信号应成为您投资过程的一部分。</p>
<h3><strong>新：AI 股票筛选器和警报</strong></h3>
<p>我们的新 AI 股票筛选器每天扫描市场，发现机会。</p>
<p>• 分红强劲的股票（收益率 3% 以上）</p>
<p>• 内部人士买入的被低估小盘股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或者从 50 多个指标中构建自己的筛选器。</p>
<p>立即免费探索</p>

<p>化工公司（Chemours Company，NYSE:CC）报告每股意外亏损 0.19 美元，营收为 14 亿美元，导致股价下跌 17%。分析师已调整预测，预计 2026 年的营收为 60.2 亿美元，每股收益为 1.21 美元，低于之前的预估。尽管盈利预期下调，目标股价仍上调 9.8% 至 24.89 美元，显示出积极的长期前景。预计化工公司的增长速度将与行业平均水平相似，年营收增长率预计为 4.6%</p>

<p>It's been a mediocre week for <strong>The Chemours Company</strong> (NYSE:CC) shareholders, with the stock dropping 17% to US$22.41 in the week since its latest quarterly results. Things were not great overall, with a surprise (statutory) loss of US$0.19 per share on revenues of US$1.4b, even though the analysts had been expecting a profit. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.</p>
<div class="lb-trans"><p>对于 <strong>Chemours 公司</strong>（纽约证券交易所代码：CC）股东来说，这一周表现平平，自最新季度财报发布以来，股价下跌了 17%，至 22.41 美元。整体情况并不理想，尽管分析师原本预期会有盈利，但公司却意外出现了每股 0.19 美元的法定亏损，营收为 14 亿美元。财报发布后，分析师们更新了他们的盈利模型，了解他们是否认为公司的前景发生了重大变化，或者一切如常，将会很有趣。我们认为读者会对分析师最新的（法定）盈利预测感兴趣，尤其是针对明年的预测。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行探索。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/249061912-earnings-and-revenue-growth-1-dark-2/1778247092634" alt="" original-src="https://images.simplywall.st/asset/chart/249061912-earnings-and-revenue-growth-1-dark-2/1778247092634"/></p>
<p>NYSE:CC Earnings and Revenue Growth May 8th 2026</p>
<div class="lb-trans"><p>纽约证券交易所：CC 盈利和收入增长 2026 年 5 月 8 日</p>
</div><p>Taking into account the latest results, the consensus forecast from Chemours' nine analysts is for revenues of US$6.02b in 2026. This reflects an okay 3.5% improvement in revenue compared to the last 12 months. Earnings are expected to improve, with Chemours forecast to report a statutory profit of US$1.21 per share. Before this earnings report, the analysts had been forecasting revenues of US$6.04b and earnings per share (EPS) of US$1.58 in 2026. The analysts seem to have become more bearish following the latest results. While there were no changes to revenue forecasts, there was a pretty serious reduction to EPS estimates.</p>
<div class="lb-trans"><p>考虑到最新的财报，Chemours 九位分析师的共识预测是 2026 年营收为 60.2 亿美元。这反映出与过去 12 个月相比，营收有 3.5% 的适度改善。预计盈利将有所改善，Chemours 预计每股报告法定盈利 1.21 美元。在这份财报发布之前，分析师们曾预测 2026 年营收为 60.4 亿美元，每股盈利（EPS）为 1.58 美元。分析师们似乎在最新财报发布后变得更加悲观。虽然营收预测没有变化，但每股盈利的预期却大幅下调。</p>
</div><p>Check out our latest analysis for Chemours</p>
<div class="lb-trans"><p>查看我们对 Chemours 的最新分析</p>
</div><p>Despite cutting their earnings forecasts,the analysts have lifted their price target 9.8% to US$24.89, suggesting that these impacts are not expected to weigh on the stock's value in the long term. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Chemours analyst has a price target of US$30.00 per share, while the most pessimistic values it at US$17.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.</p>
<div class="lb-trans"><p>尽管下调了盈利预测，分析师们仍将目标股价上调了 9.8%，至 24.89 美元，这表明这些影响预计不会在长期内对股价造成压力。然而，从这些数据中我们可以得出其他结论，因为一些投资者在评估分析师的目标股价时也喜欢考虑预期的差异。最乐观的 Chemours 分析师将目标股价定为每股 30.00 美元，而最悲观的则为 17.00 美元。对于这只股票，确实存在不同的看法，但我们认为预期范围并不够宽泛，以至于暗示情况无法预测。</p>
</div><p>Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. For example, we noticed that Chemours' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 4.6% growth to the end of 2026 on an annualised basis. That is well above its historical decline of 1.5% a year over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 5.2% per year. So while Chemours' revenues are expected to improve, it seems that it is expected to grow at about the same rate as the overall industry.</p>
<div class="lb-trans"><p>我们还可以从更大的背景来看待这些预期，例如这些预测与过去表现的对比，以及相对于行业内其他公司的预测是否更为乐观。例如，我们注意到 Chemours 的增长率预计将显著加快，预计到 2026 年营收将以年均 4.6% 的速度增长。这远高于过去五年每年 1.5% 的历史下降率。相比之下，我们的数据表明，行业内其他公司（有分析师覆盖）预计营收将以每年 5.2% 的速度增长。因此，尽管 Chemours 的营收预计将改善，但其增长速度似乎与整体行业大致相当。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.</p>
<div class="lb-trans"><p>最重要的是，分析师下调了每股盈利的预期，显示出在这些结果发布后情绪明显下降。他们还重新确认了营收预期，预计公司将以与更广泛行业相似的速度增长。目标股价也有了不错的提升，分析师们显然认为公司的内在价值正在改善。</p>
</div><p>Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Chemours going out to 2028, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>基于这一思路，我们认为公司的长期前景比明年的盈利更为重要。在 Simply Wall St，我们有 Chemours 到 2028 年的全系列分析师预估，您可以在我们的平台上免费查看。</p>
</div><p>That said, it's still necessary to consider the ever-present spectre of investment risk. <strong>We've identified 2 warning signs</strong> with Chemours (at least 1 which doesn't sit too well with us) , and understanding these should be part of your investment process.</p>
<div class="lb-trans"><p>话虽如此，仍然有必要考虑投资风险的潜在威胁。<strong>我们已识别出 Chemours 的 2 个警示信号</strong>（至少有 1 个让我们感到不安），理解这些信号应成为您投资过程的一部分。</p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：AI 股票筛选器和警报</strong></h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场，发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的股票（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士买入的被低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

Chemours 公司刚刚未能达到盈利预期，出现了意外亏损——以下是分析师的最新预测